News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Names Eric J. Vandal Vice President, Commercial Operations
SHELTON, Conn. , June 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced that Eric J.
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2014 Financial Results
Conference Call Today at 4:30pm ET
View HTML
Toggle Summary Cara Therapeutics to Announce First Quarter 2014 Financial Results on May 12, 2014
SHELTON, Conn., May 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a
View HTML
Toggle Summary Cara Therapeutics to Webcast Presentation at 13th Annual Needham Healthcare Conference
SHELTON, Conn., April 2, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that Dr.
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Conference Call Today at 4:30pm ET
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
SHELTON, Conn., March 20, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
SHELTON, Conn., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial
View HTML
Toggle Summary Cara Therapeutics Announces Pricing of Initial Public Offering
SHELTON, Conn., Jan. 31, 2014 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public
View HTML
Toggle Summary Cara Therapeutics Files Registration Statement for Proposed Initial Public Offering
SHELTON, Conn., Nov. 11, 2013 /PRNewswire/ -- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that it has filed a registration statement
View HTML
Toggle Summary Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy
Cara Therapeutics Reports Positive Results from Phase 2 Clinical Trial I.V. CR845, for Post-Operative Pain Following Bunionectomy SHELTON, Conn., Oct. 29, 2013 /PRNewswire -- Cara Therapeutics, Inc. today announced top-line results from a Phase 2 clinical trial of its novel, peripherally-acting
View HTML